- The 8 States Most Likely to Legalize Marijuana Next
- Dow 18,000: Why This Market Rally May Never Happen Again
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
- BlackBerry Classic Review: A Bold Update for CrackBerry Fans
Visudyne sales are hit by the release of Lucentis.